BRPI0823376A2 - Análagos de glucagon - Google Patents

Análagos de glucagon

Info

Publication number
BRPI0823376A2
BRPI0823376A2 BRPI0823376-4A BRPI0823376A BRPI0823376A2 BR PI0823376 A2 BRPI0823376 A2 BR PI0823376A2 BR PI0823376 A BRPI0823376 A BR PI0823376A BR PI0823376 A2 BRPI0823376 A2 BR PI0823376A2
Authority
BR
Brazil
Prior art keywords
glucagon analogs
glucagon
analogs
Prior art date
Application number
BRPI0823376-4A
Other languages
English (en)
Inventor
Eddi Meier
Ditte Riber
Marie Skovgaard
Bjarne Due Larsen
Jens Rosengren Daugaard
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of BRPI0823376A2 publication Critical patent/BRPI0823376A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0823376-4A 2008-12-15 2008-12-15 Análagos de glucagon BRPI0823376A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2008/004130 WO2010070252A1 (en) 2008-12-15 2008-12-15 Glucagon analogues

Publications (1)

Publication Number Publication Date
BRPI0823376A2 true BRPI0823376A2 (pt) 2015-06-16

Family

ID=40405072

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0823376-4A BRPI0823376A2 (pt) 2008-12-15 2008-12-15 Análagos de glucagon

Country Status (16)

Country Link
US (2) US8642540B2 (pt)
EP (1) EP2370460B1 (pt)
JP (1) JP5635530B2 (pt)
KR (1) KR20110126592A (pt)
CN (1) CN102292347A (pt)
AU (1) AU2008365556A1 (pt)
BR (1) BRPI0823376A2 (pt)
CA (1) CA2747112A1 (pt)
DK (1) DK2370460T3 (pt)
EA (1) EA020520B1 (pt)
ES (1) ES2477880T3 (pt)
IL (1) IL213480A0 (pt)
MX (1) MX2011006314A (pt)
PL (1) PL2370460T3 (pt)
WO (1) WO2010070252A1 (pt)
ZA (1) ZA201104591B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
MA34913B1 (fr) * 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
WO2013164483A1 (en) 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
AR091422A1 (es) 2012-06-14 2015-02-04 Sanofi Sa Analogos peptidicos de la exendina 4
MY170671A (en) * 2012-07-23 2019-08-26 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
ES2623979T3 (es) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Síntesis de productos peptídicos que contienen hidantoína
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AR095986A1 (es) 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
PL2986313T3 (pl) 2013-04-18 2019-12-31 Novo Nordisk A/S Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
SI3057984T1 (sl) 2013-10-17 2018-10-30 Zealand Pharma A/S Acilirani glukagonski analogi
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
EA035688B1 (ru) 2013-11-06 2020-07-27 Зилэнд Фарма А/С Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP5912150B2 (ja) * 2014-07-04 2016-04-27 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN106519015B (zh) 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
TWI705973B (zh) 2014-10-29 2020-10-01 丹麥商西蘭製藥公司 Ｇｉｐ促效劑化合物及方法
MA52253A (fr) 2015-02-17 2021-02-17 Lilly Co Eli Formulation de poudre nasale pour le traitement de l'hypoglycémie
CN107567459B (zh) 2015-03-18 2021-09-24 西兰制药公司 胰淀素类似物
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
TWI707867B (zh) 2015-04-16 2020-10-21 丹麥商西蘭製藥公司 醯化之昇糖素類似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
EP3888667B1 (en) 2016-06-09 2023-10-25 AmideBio LLC Glucagon analog and methods of use thereof
JP6651054B2 (ja) 2016-08-05 2020-02-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ−アシルトランスフェラーゼ（ｇｏａｔ）阻害薬として使用するためのオキサジアゾロピリジン誘導体
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
HUE065912T2 (hu) * 2017-08-16 2024-06-28 Dong A St Co Ltd Acilezett oxintomodulin peptid analóg
CN120887972A (zh) * 2017-11-24 2025-11-04 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
CR20200331A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat)
JP7083397B2 (ja) 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
WO2019149658A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
CA3087826A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
BR112021011595A2 (pt) 2018-12-21 2021-11-30 Jiangsu Hengrui Medicine Co Proteína biespecífica
JP7212171B2 (ja) 2019-02-05 2023-01-24 イーライ リリー アンド カンパニー グルカゴン類似体アゴニストおよびその使用方法
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
WO2021233882A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
PL4153600T3 (pl) 2020-05-22 2024-12-16 Boehringer Ingelheim International Gmbh Sposób ciągły wytwarzania 7-amino-5-metylo-[1,2,5]oksadiazolo[3,4- b]pirydynokarboksylanu alkilu
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
NZ334595A (en) 1996-09-09 2000-08-25 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
WO1999025727A2 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
JP4394279B2 (ja) 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
CN1495198A (zh) 1998-12-07 2004-05-12 �о���Ӧ�ÿ�ѧЭ��ɷ����޹�˾ 胰高血糖素样肽-1的类似物
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
PL351326A1 (en) 1999-03-17 2003-04-07 Novo Nordisk As Method for acylating peptides and novel acylating agents
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002346491A1 (en) 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
DK1891105T3 (da) 2005-06-13 2012-07-16 Imp Innovations Ltd Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
US8338368B2 (en) 2005-11-07 2012-12-25 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
NZ574215A (en) 2006-07-18 2012-07-27 Sanofi Aventis Antagonist antibody against epha2 for the treatment of cancer
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
DK2158214T3 (da) * 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2025684A1 (en) 2007-08-15 2009-02-18 Zealand Pharma A/S Glucagon analogues
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
PL2229407T3 (pl) 2008-01-09 2017-06-30 Sanofi-Aventis Deutschland Gmbh Nowe pochodne insuliny o ekstremalnie spowolnionym profilu czasu działania
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
CN102065885A (zh) 2008-04-22 2011-05-18 卡斯西部储备大学 同种型特异性的胰岛素类似物
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
AU2009260302B2 (en) 2008-06-17 2014-10-23 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
KR20110061552A (ko) 2008-07-31 2011-06-09 케이스 웨스턴 리저브 유니버시티 할로겐 안정화된 인슐린
NZ593813A (en) 2008-12-15 2013-02-22 Zealand Pharma As Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
JP2013517307A (ja) 2010-01-20 2013-05-16 ジーランド ファーマ アクティーゼルスカブ 心臓病の処置
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
EP2585482B1 (en) 2010-06-24 2019-03-27 Zealand Pharma A/S Glucagon analogues
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline

Also Published As

Publication number Publication date
DK2370460T3 (da) 2014-08-04
EP2370460B1 (en) 2014-04-30
PL2370460T3 (pl) 2014-09-30
EA201190049A1 (ru) 2012-02-28
US20110293586A1 (en) 2011-12-01
US8642540B2 (en) 2014-02-04
KR20110126592A (ko) 2011-11-23
WO2010070252A1 (en) 2010-06-24
ZA201104591B (en) 2014-11-26
JP2012511900A (ja) 2012-05-31
AU2008365556A1 (en) 2011-07-21
CA2747112A1 (en) 2010-06-24
JP5635530B2 (ja) 2014-12-03
EA020520B1 (ru) 2014-11-28
MX2011006314A (es) 2011-09-22
IL213480A0 (en) 2011-07-31
EP2370460A1 (en) 2011-10-05
ES2477880T3 (es) 2014-07-18
US20140127175A1 (en) 2014-05-08
CN102292347A (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
BRPI0823379A2 (pt) Análogos de glucagon
BRPI0823377A2 (pt) análogos de glucagon
BRPI0823376A2 (pt) Análagos de glucagon
BRPI0823378A2 (pt) análogos de glucagon
SMT201600351B (it) Composti antivirali
BRPI0922508A2 (pt) Análogos de nucleosídeo
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0911269A2 (pt) análogos de halicondrina b
BRPI0920707A2 (pt) compostos
DK2326651T3 (da) Buprenorphinanaloger
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DK2242759T3 (da) Forbindelser
DK2427449T3 (da) Vinylindazolylforbindelser
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BR112012006859A2 (pt) compostos
EP2303378A4 (en) INTERFACE
PT2231689T (pt) Novos nucleósidos 7-deazapurina citostáticos
BRPI1005525A2 (pt) compostos de azaazuleno
SMT201600045B (it) Composti tetraciclinici c7-fluoro sostituiti
BRPI0907122A2 (pt) Piridoindóis (1-azinona) substituídos
PT2260053E (pt) Análogos de oxitocina
DK2490708T3 (da) Stabiliserede glucagon-opløsninger
DK2297162T3 (da) Forbindelser
BRPI0918004A2 (pt) antagonistas de glucagon
BRPI0916432A2 (pt) compostos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]